The Effects of Ranitidine in Chronic Heart Failure Patients
|
|
- Franklin Simpson
- 5 years ago
- Views:
Transcription
1 Keerati Hantrakool, MD, and Jarkarpun Chaipromprasit, MD. Division of Cardiology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. Abstract Objectives: To determine whether the blockade of histamine H 2 -receptors using ranitidine is beneficial for the pathophysiology of chronic heart failure (CHF). Background: Because the β 1 -adrenergic blocking agent is beneficial for the pathophysiology of CHF and because activated H 2 -receptors cause activation of Gs-protein the same way as activated β 1 -adrenergic receptors do, it appears reasonable that H 2 -receptor blocking agents may be beneficial for the treatment of CHF. Methods: 50 stable symptomatic CHF patients were randomly divided into 2 groups. One group received ranitidine 300 mg/day for 16 weeks, and the other group received placebo for the same period of time. Blood levels of NTproBNP and left ventricular function obtained by echocardiography were recorded both before and after treatment in both groups. Results: Ranitidine 300 mg/d increased plasma NTproBNP levels (from 2,131 ± 3,039 pg/ml to 2,811 ± 4,714 pg/ml) while placebo decreased plasma NTproBNP levels (from 1,710 ± 1,796 pg/ml to 1,485 ± 1,660 pg/ml) but without statistical significance (p = 0.262). Conclusions: Ranitidine did not decrease NTproBNP levels in CHF patients within a 16 weeks period. Key words: Chronic Heart Failure, Ranitidine, B-Type Natriuretic Peptide, N-Terminal Pro-B-Type Natriuretic Peptide Thai Heart J 2008; 21 : E-Journal : Introduction In the past, we believed that chronic heart failure (CHF) was a Cardiorenal Model and was a process of salt and water retention (1). Although diuresis did improve the symptoms, unfortunately, no mortality benefit was obtained. Later, we recognized that a Hemodynamic Model could be the cause as a result of left ventricle (LV) dysfunction (1). In order to improve the LV contraction, we pushed the heart to its limit, using an inotropic drug, a vasodilator along with diuresis. But the result was somewhat of a paradox, the mortality rate was significantly raised (2-4). And no matter what treatment we applied to patients, the disease was still in progress (1). Presently, we have recognized the pathophysiology of CHF as a Neurohormonal Model (1). When the heart failed, it activated the catecholamine and renninangiotensin-aldosterone systems. In the early phase, it helped improve the symptoms, unfortunately in the long term; there was a greater chance for the heart to fail. Correspondence to: Keerati Hantrakool, MD. Division of Cardiology, Department of Medicine, Faculty of Medicine Chulalongkorn University, Bangkok, Thailand. To begin with, the β 1 -adrenergic receptor of the catecholamine system which are abundantly found in the myocardium is the focus. When the β 1 -receptor is activated, it couples with the stimulatory G protein (G S ) which results in accumulation of cyclic adenosine monophosphate (camp) and eventually, results in the increase of intracellular calcium ion. As mentioned above, the calcium ion stimulates the heart to beat harder but in the long term, it will lead to a necrotic and apoptotic process of the myocardium. Moreover, the camp can signal the myocardium and cause it to change its structure and function. However, recently, the evidence shows that the use of a β 1 -blocker can reduce the mortality rate and slow the progression of the disease (5-8). β 1 -blockers have been one of the mainstay treatments of CHF (9-10) but notwithstanding, it cannot be used in a certain group of patients (11). In the treatment of gastric disease, we have been using histamine-2 receptor antagonists (H 2 -blocker) for decades. But the H 2 -receptor is also found at the myocardium when it was activated. It couples the G S protein the same way, although it has less potency than the β 1 -receptor agonist (12-13). So it appears that the H 2 -blocker may have a benefit in the treatment of CHF. The objective of
2 this study was to determine whether the blockade of histamine H 2 -receptors using ranitidine is beneficial for the pathophysiology of CHF. We conducted a doubleblind randomized placebo-controlled trial using ranitidine for treatment of CHF. Methods Outpatients from King Chulalongkorn Memorial Hospital who had stable CHF were enrolled. The inclusion criteria were patients between years old with a left ventricular ejection fraction less than 45% from the following: cardiomyopathy; hypertensive heart disease; ischemic heart disease. The exclusion criteria were: pregnancy; severe liver or kidney disease; chronic obstructive pulmonary disease; pulmonary thromboembolism; isolated right-sided heart failure; severe valvular heart disease; intracardiac shunt; short life expectancy and patients who might not attend the program. This protocol was approved by the local ethical committees and the informed consent was obtained from all participating patients. Baseline characteristics were also recorded. The patients then were randomized into two groups. One treatment group received ranitidine 150 mg tablet twice a day, the other group received a placebo tablet twice a day for a period of 4 months. The quality of life was assessed by a questionnaire which asked how difficulty to do the daily activity. The echocardiography was performed by one physician who was blinded to the treatment group. Left ventricular ejection fraction (LVEF), left ventricular (LV) dimension, mitral inflow velocity and mitral annulus tissue velocity were recorded. The plasma level of amino-terminal pro-b type natriuresis peptide (NTproBNP) was measured before and after the treatment. Statistical analyses Statistical analysis was performed using the Statistical Package for the Social science version 16 (SPSS, Inc, Chicago, IL, USA). The use of Chi-square for qualitative data was applied. An independent-t-test for quantitative data and ANCOVA were also used to compare pre and post treatment data. All data presented in mean ± SD. A p-value of less than 0.05 was considered significant. Keerati Hantrakool, MD, and Jarkarpun Chaipromprasit, MD Results There were 50 patients randomized, 25 in each group. There were 2 patients who were lost to follow up in the ranitidine group and 3 patients in the placebo group. So there were 45 patients who completed the study. As shown in Table 1, there was no difference between both groups in terms of gender, age, body mass index, underlying disease and New York Heart Association (NYHA) functional class. Two thirds of the patients were male, the average age was 60 years old and most patients were in the NYHA functional class II. The average ejection fraction measured by the Simpson method was 30%. There were no differences between the groups in patients receiving Digitalis, a Loop diuretic, Nitrates, β 1 - blockers, an Angiotensin Converting Enzyme Inhibitor (ACEI), an Angiotensin II Receptor Blocker (ARB), and a Statin. However, in the ranitidine group patients received an Aldosterone Antagonist more than the placebo group. The ranitidine group had baseline plasma NT probnp levels of 2,131 ± 3,039 pg/ml while in the placebo group had 1,710 ± 1,796 pg/ml (p = 0.577). The plasma NTproBNP level in both groups was not in normal distribution due to high range nature of this value so logarithm transformation was performed which showed normal distributed data. At the end of the study, as shown in Table 2, the left ventricular internal diameter during systole in the placebo group had a slightly less value than the ranitidine group but when calculated to the fractional shortening and ejection fraction, it did not show any significant difference. There was no significant change in the NTproBNP levels among these two groups. Interestingly, the standard deviation of change in the NTproBNP levels of the ranitidine group is far greater than the Placebo group (3,818 and 589 pg/ml respectively). No patient from the placebo group complained about side effects while there were 3 patients from the ranitidine group who did. One had dizziness, one had a rash and one reported erectile dysfunction. Fortunately these side effects disappeared when ranitidine was discontinued. One patient in each group had heart failure worsening and required hospitalization.
3 Table 1. Baseline characteristics. Baseline Characteristic Gender Male Female Age Body mass index Underlying disease Diabetes melolitus Hypertension Ischemic heart disease Cardiomyopathy NYHA Functional class Fc I Fc II Fc III Systolic blood pressure Diastolic blood pressure Heart rate NT-proBNP Log (NT-proBNP) LV function LV diameter - diastole LV diameter - systole Fractional shortening LVEF (Teicholz) LVEF (Simpson) Medication Digitalis Loop diuretic Nitrate Beta-blocker ACEI ARB Spironolactone Statin Placebo group (n = 22) 16 (65.2%) 6 (34.8%) 61.7 ± ± (40.9%) 8 (36.4%) 10 (45.5%) 12 (54.5%) 0 (0%) 21 (91.3%) 2 (8.7%) ± ± ± ,710 ± 1, ± ± ± ± ± ± (50%) 17 (77.3%) 6 (27.3%) 12 (54.5%) 19 (86.4%) 3 (13.6%) 5 (22.7%) 11 (50.0%) Ranitidine group (n = 23) 15 (72.7%) 8 (27.3%) 59.2 ± ± (39.1%) 6 (26.1%) 15 (65.2%) 8 (34.8%) 1 (4.5%) 19 (88.9%) 2 (9.1%) ± ± ± ,131 ± 3, ± ± ± ± ± ± (43.5%) 20 (87.0%) 4 (17.4%) 15 (65.2%) 16 (69.6) 3 (13.0%) 13 (56.5%) 16 (69.6%) p-value
4 Keerati Hantrakool, MD, and Jarkarpun Chaipromprasit, MD Table 2. Pre and post treatment data between ranitidine and placebo group. Characteristic Weight Body mass index Systolic blood pressure Diastolic blood pressure Heart rate NT-proBNP NT-proBNP changeds Log (NT-proBNP) Log (NT-proBNP) Changeds LV function LV diameter - diastole LV diameter - systole Fractional shortening LVEF (Teicholz) LVEF (Simpson) Questionnaires score Control group (n=22) 63.3 ± ± ± ± ± ,485 ± 1, ± ± ± ± ± ± ± ± ± 14.8 Ranitidine group (n=23) 65.4 ± ± ± ± ± ,811 ± 4, ± 3, ± ± ± ± ± ± ± ± 14.9 p-value Discussion There was no statistical significance when both groups were compared in terms of NTproBNP levels, LV ejection fraction (Simpson method), NYHA function class or quality of life scores. From a previous study (14), it was shown that the usage of famotidine in CHF could decrease the plasma level of B-type natriuretic peptide (BNP). It is interesting why this result did not occur when using ranitidine. First, it may be because it is not a class effect. We know that β 1 -blockers are not a class effect to treat CHF (9-10). This may be also true for the H 2 -blockers, otherwise it could be that ranitidine has less potency than famotidine. Second, a H 2 -blocker has less potency than a β 1 - blocker, so its effect cannot outrun the β 1 -blocker s effect. And most importantly, there is an excessive amount of catecholamine stimulation (15-16) left in these patients which can reduces the H 2 -blocker s effect. Moreover, there are other proliferative signaling pathways that do not pass via the production of camp (17) and this whole process can worsen the pathophysiology of CHF. Third, the H 2 -blockers have a short half life. We had learned from a previous study that controlled release long half life metoprolol succinate form has more benefits than the short half life metoprolol tartrate form (7, 18-19). The action of the medicine used for CHF should last around the clock, and discontinuation of drug action will result in insufficiency of the treatment. Forth, there are reports about tolerance to H 2 - blockers. H 2 -blockers when administered to patients for more than a month have failed to continuously reduce gastric ph as they previously had. Whether or not this can apply to the heart is still unknown. Fifth, there are a lot of biological variations of the NTproBNP (20-22). It is said that the change in both BNP and NTproBNP value can be declared statistically significant only if their changes exceed % and 49-98% respectively (21-22). These changes may explain
5 why the NTproBNP levels vary. However, many studies show that the change in value of BNP or NTproBNP level which still don t exceed the values mentioned above (66-113% and 49-98% respectively) still have prognostic value (23). So, we may use them to monitor the treatment outcome. Sixth, the duration of treatment may be too short. According to the previous study, it has shown that a β 1 - blocker can decrease BNP levels by 3 months (24). Ranitidine may not display these benefits within the same extent and more time may be needed. Seventh, patient selection may be biased. Half of the patients enrolled received a β 1 -blocker and two thirds of all received ACEI while most of them did not receive the optimal doses of these drugs. Moreover, these are the differences from the previous trial when all the patients received optimal doses of both a β 1 -blocker and ACEI (14). Finally, the H 2 -blocker may not be of benefit for the treatment of CHF at all. The limitation of the study included the short duration of treatment, small sample size, patient selection bias as mentioned above and the echocardiographic data dependency on the operator. The questionnaires have not yet been standardized and validated. Conclusion Within 4 months, it is not beneficial to treat CHF patients using ranitidine when considering the factors of NTproBNP level; NYHA Functional class status; Left ventricular systolic function measured by echocardiography and quality of life. There should be a further study using a longer period, or using a longer half life medication such as an extended release or controlled release form. Moreover, there should be a comparison between the patients who previously received a β 1 -blocker and ones whom did not. Finally, a comparison between a group who has different levels of blood pressure, heart rate and left ventricular ejection fraction should be studied because these factors may give a totally different result. Acknowledgement The authors would like to thank Berlin Pharmaceutical Company who supplied the study drugs and Roche Diagnostics who supplied the NTproBNP Test for their generous and invaluable support. Both companies were not involved in the study design, patient selection, data collection and analysis process. References 1. Mann DL, Bristow MR. Mechanisms and Models in Heart Failure: The Biomechanical Model and Beyond. Circulation 2005; 111: Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991; 325: Cohn JN, Goldstein SO, Greenberg BH, et al. A Dose-Dependent Increase in Mortality with Vesnarinone among Patients with Severe Heart Failure. N Engl J Med 1998; 339: Feldman AM, Bristow MR, Parmley WW, et al. Effects of Vesnarinone on Morbidity and Mortality in Patients with Heart Failure. N Engl J Med 1993; 329: Packer M, Fowler MB, Roecker EB, et al. Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study. Circulation 2002; 106: A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation 1994; 90: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-congestive Heart Failure (MERIT-HF). Lancet 1999; 353: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005; 46: e Authors/Task Force M, Swedberg K, Writing C, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: Lechat P, Escolano S, Golmard JL, et al. Prognostic Value of Bisoprolol-Induced Hemodynamic Effects in Heart Failure During the Cardiac Insufficiency BIsoprolol Study (CIBIS). Circulation 1997; 96: Johnson CL, Weinstein H, Green JP. Studies on Histamine H2 Receptors Coupled to Cardiac Adenylate Cyclase: Blockade by H2 and H1 Receptor Antagonists. Mol Pharmacol 1979; 16:
6 Keerati Hantrakool, MD, and Jarkarpun Chaipromprasit, MD 13. Johnson CL, Weinstein H, Green JP. Studies on histamine H2 receptors coupled to cardiac adenylate cyclase Effects of guanylnucleotides and structural requirements for agonist activity. Biochimica et Biophysica Acta (BBA) - General Subjects 1979; 587: Kim J, Ogai A, Nakatani S, et al. Impact of Blockade of Histamine H2 Receptors on Chronic Heart Failure Revealed by Retrospective and Prospective Randomized Studies. J Am Coll Cardiol 2006; 48: Rundqvist B, Elam M, Bergmann-Sverrisdottir Y, Eisenhofer G, Friberg P. Increased Cardiac Adrenergic Drive Precedes Generalized Sympathetic Activation in Human Heart Failure. Circulation 1997; 95: Hasking GJ, Esler MD, Jennings GL, Burton D, Johns JA, Korner PI. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 1986; 73: Luttrell LM, Ferguson SS, Daaka Y, et al. Beta-arrestindependent Formation of 2 Adrenergic Receptor-Src Protein Kinase Complexes. Science 1999; 283: Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of Controlled-Release Metoprolol on Total Mortality, Hospitalizations, and Well-being in Patients With Heart Failure: The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA 2000; 283: Poole-Wilson PA, Swedberg K, Cleland JGF, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003; 362: Wu AHB, Smith A, Wieczorek S, et al. Biological variation for N-Terminal Pro-and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol 2003; 92: Bruins S, Fokkema MR, Romer JWP, et al. High Intraindividual Variation of B-Type Natriuretic Peptide (BNP) and Amino- Terminal probnp in Patients with Stable Chronic Heart Failure. Clin Chem 2004; 50: O Hanlon R, O Shea P, Ledwidge M, et al. The Biologic Variability of B-Type Natriuretic Peptide and N-Terminal Pro- B-Type Natriuretic Peptide in Stable Heart Failure Patients. J Card Fail 2007; 13: Takeda Y, Fukutomi T, Suzuki S, et al. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. Am J Cardiol 2004; 94: Troughton RW, Frampton CM, Yandle TG, Espine EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355:
7 ก ก ก ก ก.., ก.. ก : ก ก ก 2 ก ก ก : ก ก ก ก ก 2 กก ก ก ก กก ก ก 2 ก ก ก : 50 ก ก 2 ก ก ก 300 ก 16 ก ก ก ก ก NTproBNP, ก ก ก ก ก ก ก ก : ก 300 ก NT-proBNP ( ก 2,131 ± 3,039 pg/ml 2,811 ± 4,714 pg/ml) NT-proBNP ก ก ( ก 1,710 ± 1,796 pg/ml 1,485 ±1,660 pg/ml) (p = 0.262) : NT-proBNP 16
CKD Satellite Symposium
CKD Satellite Symposium Recommended Therapy by Heart Failure Stage AHA/ACC Task Force on Practice Guideline 2001 Natural History of Heart Failure Patients surviving % Mechanism of death Sudden death 40%
More informationHeart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More informationLong-Term Outcome and Tolerability of Carvedilol Therapy in Japanese Patients With Chronic Heart Failure
Long-Term Outcome and Tolerability of Carvedilol Therapy in Japanese Patients With Chronic Heart Failure Naomi Naoki Yoko Yoshie Hiroshi KAWASHIRO, MD MATSUDA, MD ENDO, MD UCHIDA, MD KASANUKI, MD, FJCC
More informationLCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor
The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction The Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection
More informationESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure
ESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure - 2005 Karl Swedberg Professor of Medicine Department of Medicine Sahlgrenska University Hospital/Östra Göteborg University Göteborg
More informationDefinition of Congestive Heart Failure
Heart Failure Definition of Congestive Heart Failure A clinical syndrome of signs & symptoms resulting from the heart s inability to supply adequate tissue perfusion. CHF Epidemiology Affects 4.7 million
More informationHeart Failure Update John Coyle, M.D.
Heart Failure Update 2011 John Coyle, M.D. Causes of Heart Failure Anderson,B.Am Heart J 1993;126:632-40 It It is now well-established that at least one-half of the patients presenting with symptoms and
More informationHeart Failure and Cardiomyopathy Center, Division of Cardiology, North Shore University Hospital, Manhasset, NY
NEUROHORMONAL ANTAGONISTS IN THE POST-MI PATIENT New Evidence from the CAPRICORN Trial: The Role of Carvedilol in High-Risk, Post Myocardial Infarction Patients Jonathan D. Sackner-Bernstein, MD, FACC
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationMetoprolol CR/XL in Female Patients With Heart Failure
Metoprolol CR/XL in Female Patients With Heart Failure Analysis of the Experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF) Jalal K. Ghali, MD; Ileana L.
More informationUnderstanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials -
Understanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials - Clinical trials Evidence-based medicine, clinical practice Impact upon Understanding pathophysiology
More informationOptimal Adrenergic Blockades in Heart Failure. Jae-Joong Kim MD, PhD Asan Medical Center, University of Ulsan, Seoul, Korea
Optimal Adrenergic Blockades in Heart Failure Jae-Joong Kim MD, PhD Asan Medical Center, University of Ulsan, Seoul, Korea Contents Harmful effects of adrenergic system in heart failure Clinical studies
More informationBeta-Blocker Therapy and Severe Heart Failure: Myth or Reality?
BETA BLOCKERS AND HF CHF JULY/AUGUST 2003 197 Beta-Blocker Therapy and Severe Heart Failure: Myth or Reality? The medical management of heart failure has undergone remarkable progress in the past 10 years.
More informationEvidence Supporting Post-MI Use of
Addressing the Gap in the Management of Patients After Acute Myocardial Infarction: How Good Is the Evidence Supporting Current Treatment Guidelines? Michael B. Fowler, MB, FRCP Beta-adrenergic blocking
More informationThe benefit of treatment with -blockers in heart failure is
Heart Rate and Cardiac Rhythm Relationships With Bisoprolol Benefit in Chronic Heart Failure in CIBIS II Trial Philippe Lechat, MD, PhD; Jean-Sébastien Hulot, MD; Sylvie Escolano, MD, PhD; Alain Mallet,
More informationCost effectiveness of beta blocker therapy for patients. with chronic severe heart failure. in Ireland. M. Barry
IMJ June 2002;95(6):174-177 Cost effectiveness of beta blocker therapy for patients with chronic severe heart failure in Ireland M. Barry Irish National Centre for Pharmacoeconomics Address for correspondence
More informationTERAPIA DELLO SCOMPENSO DAI BETA- BLOCCANTI AGLI ARNI (ARNI SI ARNI NO) Iseo 10 Novembre 2018
TERAPIA DELLO SCOMPENSO DAI BETA- BLOCCANTI AGLI ARNI (ARNI SI ARNI NO) Iseo 10 Novembre 2018 Carlo Lombardi Cattedra di Cardiologia Università e Spedali Civili di Brescia All-cause mortality in the European
More informationHeart Failure Management Update
Heart Failure Management Update Rafique Ahmed, MD, PhD, FACC, FCPS Consultant Cardiac Electrophysiologist Baltimore, Maryland, USA Heart Failure - Definition The situation when the heart is incapable of
More informationCase 1: A 54-year-old man with
CLINICIAN UPDATE -Blockers in Chronic Heart Failure Mihai Gheorghiade, MD; Wilson S. Colucci, MD; Karl Swedberg, MD Case 1: A 54-year-old man with a history of myocardial infarction (MI) presented with
More information2017 Summer MAOFP Update
2017 Summer MAOFP Update. Cardiology Update 2017 Landmark Trials Change Practice Guidelines David J. Strobl, DO, FNLA Heart Failure: Epidemiology More than 4 million patients affected 400,000 new cases
More informationBeta-blockers in heart failure: evidence put into practice
Beta-blockers in heart failure: evidence put into practice John McMurray Professor of Medical Cardiology, University of Glasgow & Consultant Cardiologist,Western Infirmary, Glasgow, UK Eugene Braunwald
More informationSatish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care
Satish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care None Fig. 1. Progression of Heart Failure.With each hospitalization for acute heart failure,
More informationThe role of angiotensin II receptor blockers in the management of heart failure
European Heart Journal Supplements (2005) 7 (Supplement J), J10 J14 doi:10.1093/eurheartj/sui057 The role of angiotensin II receptor blockers in the management of heart failure John J.V. McMurray* Department
More informationClinical Research on Brain Natriuretic Peptide Guiding the Application of 1 Receptor Blocker in Patients with Moderate to Severe Heart Failure
Original Article Acta Cardiol Sin 2015;31:52 58 doi: 10.6515/ACS20140728A Heart Failure Clinical Research on Brain Natriuretic Peptide Guiding the Application of 1 Receptor Blocker in Patients with Moderate
More informationDrugs Used in Heart Failure. Assistant Prof. Dr. Najlaa Saadi PhD pharmacology Faculty of Pharmacy University of Philadelphia
Drugs Used in Heart Failure Assistant Prof. Dr. Najlaa Saadi PhD pharmacology Faculty of Pharmacy University of Philadelphia Heart Failure Heart failure (HF), occurs when cardiac output is inadequate to
More informationPerformance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set
Unless indicated, the PINNACLE Registry measures are endorsed by the American College of Cardiology Foundation and the American Heart Association and may be used for purposes of health care insurance payer
More informationDisclosures for Presenter
A Comparison of Angiotensin Receptor- Neprilysin Inhibition (ARNI) With ACE Inhibition in the Long-Term Treatment of Chronic Heart Failure With a Reduced Ejection Fraction Milton Packer, John J.V. McMurray,
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationDisclosure of Relationships
Disclosure of Relationships Over the past 12 months Dr Ruilope has served as Consultant and Speakers Bureau member of Astra-Zeneca, Bayer, Daiichi-Sankyo, Menarini, Novartis, Otsuka, Pfizer, Relypsa, Servier
More informationBehandlungsalgorithmus bei Herzinsuffizienz mit reduzierter Auswurffraktion
Behandlungsalgorithmus bei Herzinsuffizienz mit reduzierter Auswurffraktion Professor Dr. med. Roger Hullin Leiter Programm für Schwere Herzinsuffizienz, VAD & Herztransplantation Suisse Romande Klinik
More informationHEART FAILURE. Heart Failure in the US. Heart Failure (HF) 3/2/2014
HEART FAILURE Martina Frost, PA-C Desert Cardiology of Tucson Northwest Medical Center March 2014 Heart Failure in the US Prevalence - ~5 million 650,000 new cases annually 300,000 deaths annually Leading
More informationTreating HF Patients with ARNI s Why, When and How?
Treating HF Patients with ARNI s Why, When and How? 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La Jolla, CA Barry Greenberg M.D. Distinguished Professor
More informationI know the trials in heart failure but how do I manage my patient? Dosing of neurohormones antagonists
I know the trials in heart failure but how do I manage my patient? Dosing of neurohormones antagonists Alessandro Fucili (Ferrara, IT) Massimo F Piepoli (Piacenza, IT) Clinical Case: 82 year old woman
More informationThe Management of Heart Failure after Biventricular Pacing
The Management of Heart Failure after Biventricular Pacing Juan M. Aranda, Jr., MD University of Florida College of Medicine, Division of Cardiovascular Medicine, Gainesville, Florida Approximately 271,000
More informationChecklist for Treating Heart Failure. Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute
Checklist for Treating Heart Failure Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute Novartis Disclosure Heart Failure (HF) a complex clinical syndrome that arises secondary to abnormalities
More informationESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Patients t with acute heart failure frequently develop chronic heart failure Patients with chronic heart failure frequently decompensate acutely ESC Guidelines for the Diagnosis and A clinical response
More informationNT-proBNP: Evidence-based application in primary care
NT-proBNP: Evidence-based application in primary care Associate Professor Rob Doughty The University of Auckland, Auckland City Hospital, Auckland Heart Group NT-proBNP: Evidence in Primary Care The problem
More informationFrom PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group
From PARADIGM-HF to Clinical Practice Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group PARADIGM-HF: Inclusion Criteria Chronic HF NYHA FC II IV with LVEF
More informationAdvanced Care for Decompensated Heart Failure
Advanced Care for Decompensated Heart Failure Sara Kalantari MD Assistant Professor of Medicine, University of Chicago Advanced Heart Failure, Mechanical Circulatory Support and Cardiac Transplantation
More informationHeart failure. Complex clinical syndrome. Estimated prevalence of ~2.4% (NHANES)
Heart failure Complex clinical syndrome caused by any structural or functional impairment of ventricular filling or ejection of blood Estimated prevalence of ~2.4% (NHANES) Etiology Generally divided into
More informationPharmacological Treatment for Chronic Heart Failure. Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014
Pharmacological Treatment for Chronic Heart Failure Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014 1 ACC/AHA 2005 guideline update for Diagnosis & management of CHF in the Adult -SA Hunt
More informationTreatment of Heart Failure: Current Recommendation Waiz A
Treatment of Heart Failure: Current Recommendation Waiz A The impaired left ventricular emptying that characterizes heart failure may result from a variety of cardiac diseases, including myocardial ischaemia
More informationHeart failure. Failure? blood supply insufficient for body needs. CHF = congestive heart failure. increased blood volume, interstitial fluid
Failure? blood supply insufficient for body needs CHF = congestive heart failure increased blood volume, interstitial fluid Underlying causes/risk factors Ischemic heart disease (CAD) 70% hypertension
More informationCongestive Heart Failure 2015
Definition Congestive Heart Failure 215 JP Mehegan/ Mercy Cardiology n Cardiac failure; Congestive heart failure; Chronic heart failure (synonyms) n When the heart is unable to pump sufficiently and at
More informationJournal of the American College of Cardiology Vol. 37, No. 7, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 37, No. 7, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01269-4 Plasma
More informationDrugs acting on the reninangiotensin-aldosterone
Drugs acting on the reninangiotensin-aldosterone system John McMurray Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham and Women s Hospital, Boston & Visiting Professor, Harvard Medical School
More informationMetoprolol Succinate SelokenZOC
Metoprolol Succinate SelokenZOC Blood Pressure Control and Far Beyond Mohamed Abdel Ghany World Health Organization - Noncommunicable Diseases (NCD) Country Profiles, 2014. 1 Death Rates From Ischemic
More informationWhat s new in heart failure management? Yonsei Cardiovascular Center Yonsei University College of Medicine
What s new in heart failure management? Yonsei Cardiovascular Center Yonsei University College of Medicine Current Guideline of Treatment Asymptomatic Mild/Mod Severe Refractory Correct Cause: Arrhythmias
More informationEffects of Cilostazol in Patients With Bradycardiac Atrial Fibrillation
J Cardiol 2001 ; 37: 27 33 Effects of Cilostazol in Patients With Bradycardiac Atrial Fibrillation 1 2 1 Masato Kouki KISHIDA, MD WATANABE, MD Abstract Objectives. Cilostazol, an antithrombotic agent,
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Is there a mortality risk associated with aspirin use in heart failure? Results from a large community based cohort Margaret Bermingham, Mary-Kate Shanahan, Saki Miwa,
More informationESC Guidelines for diagnosis and management of HF 2012: What s new? John Parissis, MD Athens, GR
ESC Guidelines for diagnosis and management of HF 2012: What s new? John Parissis, MD Athens, GR Disclosures ALARM INVESTIGATOR RESEARCH GRANTS BY ABBOTT USA AND ORION PHARMA The principal changes from
More informationA patient with decompensated HF
A patient with decompensated HF Professor Michel KOMAJDA University Pierre & Marie Curie Pitie Salpetriere Hospital Department of Cardiology Paris (France) Declaration Of Interest 2010 Speaker : Servier,
More information1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?
Disclosure Heart Failure Guideline Review and Update I have had no financial relationship over the past 12 months with any commercial sponsor with a vested interest in this presentation. Natalie Beiter,
More informationHeart Failure Clinician Guide JANUARY 2016
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.
More informationHeart Failure with preserved ejection fraction (HFpEF)
Heart Failure with preserved ejection fraction (HFpEF) Dr. Pierpaolo Pellicori Hull York Medical School Kingston-upon-Hull United Kingdom Conflict of interest: none Heart failure is a contemporary problem
More informationGuidelines for the Treatment of HEART FAILURE
Guidelines for the Treatment of HEART FAILURE Leslie W. Miller University of Minnesota HEART FAILURE Facts 5 million patients with CHF in U.S. 55, new cases/year 3, deaths/year 4 fold increase in risk
More informationOptimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure
Optimal blockade of the Renin- Angiotensin-Aldosterone Aldosterone- (RAA)-System in chronic heart failure Jan Östergren Department of Medicine Karolinska University Hospital Stockholm, Sweden Key Issues
More informationIs beta-blockade useful in heart failure patients with atrial fibrillation? An analysis of data from two previously completed prospective trials
The European Journal of Heart Failure 4 (2002) 489 494 Is beta-blockade useful in heart failure patients with atrial fibrillation? An analysis of data from two previously completed prospective trials Jeffrey
More informationHeart Failure Background, recognition, diagnosis and management
Heart Failure Background, recognition, diagnosis and management Speaker bureau: Novartis At the conclusion of this activity, participants will be able to: Recognize signs and symptoms of heart failure
More informationHeart Failure A Team Approach Background, recognition, diagnosis and management
Heart Failure A Team Approach Background, recognition, diagnosis and management Speaker bureau: Novartis At the conclusion of this activity, participants will be able to: Recognize signs and symptoms of
More informationHeart Failure Treatments
Heart Failure Treatments Past & Present www.philippelefevre.com Background Background Chronic heart failure Drugs Mechanical Electrical Background Chronic heart failure Drugs Mechanical Electrical Sudden
More informationCombination of renin-angiotensinaldosterone. how to choose?
Combination of renin-angiotensinaldosterone system inhibitors how to choose? Karl Swedberg Professor of Medicine Sahlgrenska Academy University of Gothenburg karl.swedberg@gu.se Disclosures Research grants
More informationCongestive Heart Failure: Outpatient Management
The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationIntroduction to Heart Failure. Mauricio Velez, M.D. Transplant Cardiologist APACVS 2018 April 5-7 Miami, FL
Introduction to Heart Failure Mauricio Velez, M.D. Transplant Cardiologist APACVS 2018 April 5-7 Miami, FL Disclosures No relevant financial relationships to disclose Objectives and Outline Define heart
More informationSummary/Key Points Introduction
Summary/Key Points Introduction Scope of Heart Failure (HF) o 6.5 million Americans 20 years of age have HF o 960,000 new cases of HF diagnosed annually o 5-year survival rate for HF is ~50% Classification
More informationUpdate on therapy for acute and chronic heart failure for family physicians Applying advances in outpatient management
Update on therapy for acute and chronic heart failure for family physicians Applying advances in outpatient management Authors: Abdullah Alsaeedi MD, FRCPC Division of internal Medicine Aljahra Hospital
More informationHeart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist
Heart Failure Management Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist Heart failure prevalence is expected to continue to increase¹ 21 MILLION ADULTS WORLDWIDE
More informationReceived 24 January 2007; received in revised form 27 February 2007; accepted 5 July 2007
European Journal of Heart Failure 9 (2007) 795 801 www.elsevier.com/locate/ejheart Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a β-blocker: Results from
More informationPravin Manga Division of Cardiology Department of Medicine University of Witwatersrand
Pravin Manga Division of Cardiology Department of Medicine University of Witwatersrand Overview Definition Epidemiology Biomarkers Treatment Clinical Heart Failure: Syndrome in which patients have typical
More informationUpdates in Congestive Heart Failure
Updates in Congestive Heart Failure GREGORY YOST, DO JOHNSTOWN CARDIOVASCULAR ASSOCIATES 1/28/2018 Disclosures Edwards speaker on Sapien3 valves (TAVR) Stages A-D and NYHA Classes I-IV Stage A: High risk
More informationDisclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017
Advances in Chronic Heart Failure Management Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 I have nothing to disclose Disclosures 1 Goal statement To review recently-approved therapies
More informationDisclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17
Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program May 22, 2017 Goal statement To review recently-approved therapies
More informationCT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD
CT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD Clinical syndrome resulting from a structural or functional cardiac disorder that impairs the ability of the heart to
More informationHEART FAILURE PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
HEART FAILURE PHARMACOLOGY University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 LEARNING OBJECTIVES Understand the effects of heart failure in the body
More informationGuideline-Directed Medical Therapy
Guideline-Directed Medical Therapy Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation OPTIMAL THERAPY (As defined in
More informationHeart Failure Clinician Guide JANUARY 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.
More informationBeta-Adrenergic Blocking Agents in Heart Failure
Update Beta-Adrenergic Blocking Agents in Heart Failure Michel Batlouni, Denilson Campos de Albuquerque São Paulo, SP Rio de Janeiro, RJ - Brazil Cardiac dysfunction in heart failure is widely recognized
More information12 th Annual Biomarkers in Heart Failure and Acute Coronary Syndromes: Diagnosis, Treatment and Devices. Heart Rate as a Cardiovascular Biomarker
12 th Annual Biomarkers in Heart Failure and Acute Coronary Syndromes: Diagnosis, Treatment and Devices Heart Rate as a Cardiovascular Biomarker Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine,
More informationHeart Failure. Dr. Alia Shatanawi
Heart Failure Dr. Alia Shatanawi Left systolic dysfunction secondary to coronary artery disease is the most common cause, account to 70% of all cases. Heart Failure Heart is unable to pump sufficient blood
More informationTake-home Messages from Recent Heart Failure Trials: Heart Rate as a Target
Take-home Messages from Recent Heart Failure Trials: Heart Rate as a Target JEFFREY S. BORER, M.D. Professor and Chairman, Department of Medicine and Chief, Division of Cardiovascular Medicine; Director,
More informationBeta blockers as cardioprotective agents: Part II Focus on prevention of sudden
Beta blockers as cardioprotective agents: Part II Focus on prevention of sudden cardiac death Sidney Goldstein, MD From the Division of Cardiovascular Medicine, Henry Ford Heart and Vascular Institute,
More informationClinical Investigation and Reports. Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure
Clinical Investigation and Reports Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS)
More informationHeart Failure. Disclosures. Objectives: 8/28/2017. This is not a virus. It doesn t go away. none
Heart Failure This is not a virus. It doesn t go away Shelley Wojtaszczyk, FNP-C, CHFN Heart Failure Program Coordinator Mercy Hospital of Buffalo none Disclosures Objectives: Defining and identifying
More informationOutline. Pathophysiology: Heart Failure. Heart Failure. Heart Failure: Definitions. Etiologies. Etiologies
Outline Pathophysiology: Mat Maurer, MD Irving Assistant Professor of Medicine Definitions and Classifications Epidemiology Muscle and Chamber Function Pathophysiology : Definitions An inability of the
More informationNew in Heart Failure SGK autumn session 2012
New in Heart Failure SGK autumn session 2012 Roger Hullin Cardiology Department of Internal Medicine Centre Universitaire Hospitaler Vaudois University of Lausanne ESC Heart Failure Guidelines 2012 Classes
More informationLITERATURE REVIEW: HEART FAILURE. Chief Residents
LITERATURE REVIEW: HEART FAILURE Chief Residents Heart Failure EF 40% HFrEF Problem with contractility EF 40-50% HFmrEF EF > 50% HFpEF Problem with filling/relaxation RISK FACTORS Post MI HTN DM Obesity
More informationAntialdosterone treatment in heart failure
Update on the Treatment of Chronic Heart Failure 2012 Antialdosterone treatment in heart failure 전남의대윤현주 Chronic Heart Failure Prognosis of Heart failure Cecil, Text book of Internal Medicine, 22 th edition
More informationReview Article. Pharmacotherapy of Heart Failure with Reduced LVEF. Sachin Mukhedkar, Ajit Bhagwat
Review Article Vidarbha Journal of Internal Medicine Volume 22 January 2017 Pharmacotherapy of Heart Failure with Reduced LVEF 1 2 Sachin Mukhedkar, Ajit Bhagwat ABSTRACT Heart failure with reduced ejection
More informationANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITORS IN HEART FAILURE FROM CHD
ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITORS IN HEART FAILURE FROM CHD Karen Stout, MD FACC Professor, Medicine/Pediatrics University of Washington Seattle, WA USA No disclosures Case 35 year old man with
More informationReport on the Expert Group Meeting of Paediatric Heart Failure, London 29 November 2010
Report on the Expert Group Meeting of Paediatric Heart Failure, London 29 November Clinical trials in Paediatric Heart Failure List of participants: Michael Burch, Hugo Devlieger, Angeles Garcia, Daphne
More informationThe burden of disease in patients with. What s New. Heart Failure? In this article:
What s New in Heart Failure? A large part of the population is at risk for congestive heart failure. With one-year mortality rates approaching 40%, it is crucial to understand the newest and best treatment
More informationTopic Page: congestive heart failure
Topic Page: congestive heart failure Definition: congestive heart f ailure from Merriam-Webster's Collegiate(R) Dictionary (1930) : heart failure in which the heart is unable to maintain an adequate circulation
More informationAldosterone Antagonism in Heart Failure: Now for all Patients?
Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C
More informationSystolic Dysfunction Clinical/Hemodynamic Guide for Management; New Medical and Interventional Therapeutic Challenges
Systolic Dysfunction Clinical/Hemodynamic Guide for Management; New Medical and Interventional Therapeutic Challenges Clyde W. Yancy, MD, MSc, FACC, FAHA, MACP Magerstadt Professor of Medicine Professor,
More informationΔακτυλίτιδα και Ινότροπα Φάρμακα στην Καρδιακή Ανεπάρκεια. Ι.Κανονίδης
Δακτυλίτιδα και Ινότροπα Φάρμακα στην Καρδιακή Ανεπάρκεια Ι.Κανονίδης Cardiac Glycosides Chronic Congestive Heart Failure DIGOXIN Na-K ATPase Na + K + Na-Ca Exchange Na + Ca ++ Ca ++ K + Na + Myofilaments
More informationHeart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)
Pharmacology I. Definitions A. Heart Failure (HF) Heart Failure Ezra Levy, Pharm.D. HF Results when one or both ventricles are unable to pump sufficient blood to meet the body s needs There are 2 types
More informationHeart Failure: Guideline-Directed Management and Therapy
Heart Failure: Guideline-Directed Management and Therapy Guideline-Directed Management and Therapy (GDMT) was developed by the American College of Cardiology and American Heart Association to define the
More information